A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients

NCT00987935 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

134

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Sorafenib
DRUG: BIBF 1120

Sponsor

Boehringer Ingelheim